Chronic Hand Eczema Market Size is anticipated to Increase During the Study Period 2019-2032 | Companies- LEO Pharma, Japan Tobacco, Asana Biosciences, and Others

The Chronic Hand Eczema market report provides current treatment practices, Chronic Hand Eczema emerging drugs, Chronic Hand Eczema market share of the individual therapies, current and forecasted Chronic Hand Eczema market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Chronic Hand Eczema treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Chronic Hand Eczema market.

Discover more about therapies set to grab major Chronic Hand Eczema Market Share @ Chronic Hand Eczema Market Size- https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chronic Hand Eczema Market Report
• The current understanding of Chronic Hand Eczema has improved in recent decades, leading to growing awareness, improved management, and better outcomes.
• As per DelveInsight estimate, female are most commonly affected as compared to males in case of CHE in the 7MM.
• In 2022 there were approximately 63,516,151 cases in the 7MM in which the US accounted for maximum cases (41%) out of total 7MM and Japan accounted for 17%.
• The leading Chronic Hand Eczema Companies include Leo Pharma/Japan Tobacco Inc, Asana Biosciences, and others
• Promising Chronic Hand Eczema Pipeline Therapies include Delgocitinib, ASN002 (Gusacitinib), Pimecrolimus Cream 1%, Alitretinoin, Acitretin, and others

Chronic Hand Eczema Epidemiology Segmentation in the 7MM
• Total Chronic Hand Eczema Prevalent Cases
• Chronic Hand Eczema Gender specific Diagnosed Prevalent Cases
• Chronic Hand Eczema Severity specific Diagnosed Prevalent Cases
• Chronic Hand Eczema Diagnosed Prevalent Cases
• Chronic Hand Eczema Treatable Cases

Download the report to understand which factors are driving Chronic Hand Eczema Epidemiology Trends @ Chronic Hand Eczema Epidemiological Insights- https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Hand Eczema Overview
Chronic Hand Eczema refers to an eczematous process that lasts more than 3 months or relapses twice or more often per year. Scaling and fissures are found in most cases. Hyperkeratosis is present in chronic irritant and allergic HE but is also found in the endogenous hyperkeratotic HE and in other chronic cases.

Chronic Hand Eczema Market Landscape
The current management of CHE is nonspecific and commonly involves skin hydration, emollients, avoidance of irritants, and therapeutic intervention with topical corticosteroids (TCS) or systemic immunosuppressive therapies, such as short-term oral corticosteroids, and azathioprine, methotrexate, retinoids, and cyclosporine. The present treatment landscape is classified into four groups: topical corticosteroids, topical calcineurin inhibitors, UV therapy including PUVA, and others (Iontophoresis therapy, other topical therapies, salicylic acid, etc.).

To know more about Chronic Hand Eczema Therapies options, visit @ Chronic Hand Eczema Therapeutics Market- https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recent Developmental Activities in the Chronic Hand Eczema Treatment Landscape

• Delgocitinib - Leo Pharma/Japan Tobacco Inc  Delgocitinib is an investigational, small-molecule, pan-Janus kinase (JAK) inhibitor blocking all four members of the JAK family (JAK1-3, tyrosine kinase 2), which is being developed by Leo Pharma. The JAK-STAT (signal transducer and activator of transcription protein) pathway plays a key role in the pathogenesis of many dermatological diseases. It also inhibits the activation of innate and adaptive immune cells, improves skin barrier function by modulating keratinocyte differentiation, inhibits T-helper (Th)1-, Th2-, Th17- and Th22-type inflammatory responses, and has antipruritic properties. The drug is currently in Phase III of clinical development for the treatment of chronic hand eczema patients.

• Gusacitinib (ASN002) : Asana Biosciences  ASN002, an oral, potent, dual Janus Kinase (JAK) and spleen tyrosine kinase (SYK) inhibitor. Both JAK and SYK kinases are involved in both cytokine production and signaling and have been implicated in the pathogenesis of various types of lymphomas, solid tumors, myeloproliferative, and inflammation disorders.  Currently, Asana Biosciences is evaluating ASN002 in Phase II study in individuals with severe chronic HE refractory to topical corticosteroids.

Chronic Hand Eczema Emerging Drugs

• ARQ-252: Arcutis Biotherapeutics
ARQ-252 is a topical janus kinase 1 (JAK1) inhibitor that has promise as a novel treatment for inflammatory dermatologic diseases, including chronic hand eczema and vitiligo. Many inflammatory cytokines and other signaling molecules rely on the JAK pathway, and specifically JAK1, which plays a central role in immune system function. Inhibition of JAK1 has been shown to treat a range of inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn's disease, and atopic dermatitis. ARQ-252 is differentiated from other topical JAK inhibitors by its high potency and unique high selectivity against JAK1 compared to JAK2. ARQ-252's selectivity for JAK1 may confer important safety advantages compared to other topical JAK inhibitors.

• ASN002: Asana BioSciences
ASN002 (Gusacitinib) is a potent dual inhibitor of JAK and SYK kinases, which are involved in both cytokine production and signaling. ASN002 inhibits JAK-mediated cytokine signaling and JAK-SYK mediated T- and B-cell proliferation and function. Gusacitinib completed Phase 2 clinical evaluation in moderate-to-severe chronic hand eczema (CHE) patients.

Learn more about the Chronic Hand Eczema Pipeline Therapies in clinical trials @ Chronic Hand Eczema SWOT Analysis, Unmet Needs, Reimbursement, and Patient Journey- https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Hand Eczema Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Chronic Hand Eczema Companies- Leo Pharma/Japan Tobacco Inc, Asana Biosciences, and others
• Chronic Hand Eczema Pipeline Therapies include Delgocitinib, ASN002 (Gusacitinib), Pimecrolimus Cream 1%, Alitretinoin, Acitretin, and others
• Chronic Hand Eczema Market Dynamics: Chronic Hand Eczema Market Drivers and Barriers
• Chronic Hand Eczema Market Access and Reimbursement, Unmet Needs and Emerging Drugs

Discover more about Chronic Hand Eczema Drugs in development @ Chronic Hand Eczema Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Chronic Hand Eczema (CHE)
3. Competitive Intelligence Analysis for Chronic Hand Eczema (CHE)
4. Chronic Hand Eczema (CHE): Market Overview at a Glance
5. Chronic Hand Eczema (CHE): Disease Background and Overview
6. Patient Journey
7. Chronic Hand Eczema (CHE) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Hand Eczema (CHE) Unmet Needs
10. Key Endpoints of Chronic Hand Eczema (CHE) Treatment
11. Chronic Hand Eczema (CHE) Marketed Products
12. Chronic Hand Eczema (CHE) Emerging Therapies
13. Chronic Hand Eczema (CHE): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Chronic Hand Eczema Market Outlook
16. Access and Reimbursement Overview of Chronic Hand Eczema (CHE)
17. KOL Views
18. Chronic Hand Eczema Market Drivers
19. Chronic Hand Eczema Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.